Back to Search
PAUL HARMATZ, MD
MD
Pediatric Gastroenterology Physician
NPI: 1255435301Individual
Specialties, Licenses & Credentials
Pediatric Gastroenterology PhysicianPrimary
Pediatrics — Pediatric Gastroenterology
Code: 2080P0206X
G35255(CA)
Research & Publications (20)
Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase.
PMID 18502162·Mol Genet Metab·2008
3-trial
Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia.
PMID 18430624·Bone·2008
4-observational
Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia.
PMID 18556414·Haematologica·2008
3-trial
Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
PMID 17614825·Br J Haematol·2007
3-trial
Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.
PMID 16647419·J Pediatr·2006
3-trial
Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a phase I/II study.
PMID 15895715·Acta Paediatr Suppl·2005
3-trial
Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
PMID 15930196·Pediatrics·2005
3-trial
Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
PMID 15126989·J Pediatr·2004
3-trial
Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy.
PMID 10891433·Blood·2000
3-trial
Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study.
PMID 19261295·J Pediatr·2009
3-trial
Folate concentrations in pediatric patients with newly diagnosed inflammatory bowel disease.
PMID 19116333·Am J Clin Nutr·2009
8-other
Patterns of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease.
PMID 19536851·Am J Hematol·2009
8-other
Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme) therapy.
PMID 18418554·Int Ophthalmol·2009
5-case
Italian Society of Hematology guidelines for thalassemia and non-invasive iron measurements.
PMID 19109216·Haematologica·2009
8-other
Altered iron metabolism in children with human immunodeficiency virus disease.
PMID 19322737·Pediatr Hematol Oncol·2009
8-other
The effect of vitamins C and E on biomarkers of oxidative stress depends on baseline level.
PMID 18455517·Free Radic Biol Med·2008
2-rct
Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial.
PMID 18469351·Haematologica·2008
3-trial
Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions.
PMID 18513257·Transfusion·2008
4-observational
Pharmacokinetics of sapropterin in patients with phenylketonuria.
PMID 19026037·Clin Pharmacokinet·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 747 52ND ST
OAKLAND, CA 94609 - Phone
- (510) 428-3058
Quick Facts
- NPI
- 1255435301
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile